LANGHORNE, PA — NEXGEL Inc. (Nasdaq: NXGL) said it will pay $15 million upfront to license and acquire a portfolio of regenerative biomaterial products from Celularity Inc. (Nasdaq: CELU), with up to $20 million in additional milestone payments tied to future sales targets.
The company said the acquisition is expected to significantly expand its business and could approximately triple annual revenue to about $35 million.
NEXGEL said the portfolio includes six commercial-stage products used in tendon repair, skin grafts, and bone growth.
The products have been in clinical use for more than a decade and have established insurance reimbursement pathways, according to the company.
NEXGEL said the transaction is expected to add an experienced commercial and scientific team and expand its capabilities in the medical technology sector.
Chief Executive Officer Adam Levy said the milestone payments would depend on the portfolio meeting certain net sales targets.
“In consideration for the portfolio, NEXGEL will pay an upfront cash payment of $15 million,” Levy said. “Going forward, milestone payments of up to $20 million may potentially be paid based on the portfolio achieving various net sales targets in the future.”
The company said the potential milestone payments would represent additional upside tied to the commercial performance of the products.
NEXGEL said the transaction remains subject to customary closing conditions and financing.
Additional details about the agreement were disclosed in a Form 8-K filed March 10, 2026, with the U.S. Securities and Exchange Commission and available on the SEC’s EDGAR website.
Langhorne, Pennsylvania-based NEXGEL manufactures hydrogel products used in healthcare, beauty, and over-the-counter consumer applications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.